Latest news with #ScientificAdvisoryBoard
Yahoo
2 days ago
- Health
- Yahoo
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression
- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo's CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment-resistant depression (TRD) - SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced the formation of its neuroscience-focused Scientific Advisory Board (SAB) comprised of distinguished experts in the field. The SAB will be chaired by Charles B. Nemeroff, M.D., Ph.D., Chair and Professor of the Department of Psychiatry and Behavioral Sciences at Dell Medical School at The University of Texas at Austin. Dr. Nemeroff served as president of the American College of Psychiatrists and the American College of Neuropsychopharmacology, and is past-president of the Anxiety and Depression Association of America (ADAA). 'We are extremely honored to welcome such a distinguished group of scientific leaders to join our efforts at Denovo Biopharma as we work towards addressing a major unmet need in the psychiatry field with a novel precision medicine,' said Wen Luo, Ph.D., Chief Executive Officer of Denovo Biopharma. 'As we prepare our lead asset, DB104, to enter a biomarker-guided Phase 3 study in TRD, we believe their guidance will be instrumental in shaping both our clinical development strategy and our regulatory path forward. We are thankful for their support and look forward to collaborating as we work to advance a first-in-class, potentially transformative therapy for patients with TRD.' Other members of Denovo's neuroscience Scientific Advisory Board include: Stephen Brannan, M.D., is a neuroscience drug development expert with over 15 years of industry experience. He most recently served as Chief Medical Officer at Karuna Therapeutics, where he was instrumental in the development of CobenfyTM for the treatment of schizophrenia, which was later acquired by Bristol Myers Squibb for $14 billion. Prior to Karuna, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affairs at Forum Pharmaceuticals. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta®, Exelon Patch®, Trintellix®, and Vagal Nerve Stimulation for TRD during his tenures at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. Sanjay Mathew, M.D., is Professor of Psychiatry and Behavioral Sciences, Director of Mood and Anxiety Disorders Program, and Vice Chair for Research at Baylor College of Medicine. He is currently ADAA's President-Elect and Chief Medical Officer. Dr. Mathew is a leading expert in the areas of experimental therapeutics and pathophysiology of TRD, suicide, and PTSD. About DB104 (biomarker-guided liafensine) Liafensine is a first-in-class triple reuptake inhibitor targeting transporters for serotonin, norepinephrine, and dopamine. It was licensed from Albany Molecular Research, Inc. (now Curia) and was previously developed by Bristol-Myers Squibb (BMS), who had conducted two large Phase 2b clinical trials in non-selected TRD patient population. Denovo's unique artificial intelligence (AI) and whole genome sequencing (WGS)-based Denovo Genomic Marker (DGM™) biomarker platform allowed discovery of a novel genetic biomarker at the ANK3 gene, with a strong correlation of ANK3-positive status with liafensine's efficacy in the BMS studies. Denovo's ENLIGHTEN Phase 2b study results prospectively demonstrated the use of ANK3 as a predictive biomarker for liafensine's efficacy in TRD patients, a first for genetic biomarkers in psychiatry. About Denovo Biopharma Denovo Biopharma LLC is a clinical-stage biopharmaceutical company that uses novel biomarker approaches to execute efficient clinical trials in targeted patient subpopulations to increase the probability of success. Denovo has seven late-stage drugs in its pipeline addressing major unmet medical needs in central nervous system diseases and oncology, most of which are first in class drugs with global rights. Visit for additional information. Investor Contact: Stephen Jasper Gilmartin Group stephen@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board
Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit's BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit's Scientific Advisory Board alongside Commit's CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the Scientific Advisory Board AARHUS, Denmark, June 4, 2025 /PRNewswire/ -- Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat autoimmune disease and cancer, today announces the formation of its Scientific Advisory Board (SAB) with the appointment of five leading industry and scientific experts. The newly formed board will be co-chaired by leading antibody expert Janine Schuurman, PhD, and Commit's CEO Mikkel Wandahl Pedersen. They are being joined by Professor of Molecular Immunology, former Genmab SVP and serial biotech entrepreneur Paul Parren, PhD; former Regeneron SVP of Oncology Research Gavin Thurston, PhD; esteemed immunologist Susan Kalled, PhD, who has previously worked as CSO at both Dianthus Therapeutics and Compass Therapeutics; and molecular biologist Esper Boel, PhD, previously CTO at Symphogen and Corporate Vice President and Head of Biotechnology at Novo Nordisk. The SAB will provide constructive feedback to Commit's management team and Board of Directors as the Company further develops its Bispecific Complement Engager (BiCE™) technology platform. Mikkel Wandal Pedersen, PhD, Chief Executive Officer of Commit Biologics, said: "Forming Commit's Scientific Advisory Board is a pivotal step in our mission to bring first-in-class complement engager therapeutics to patients. I am very pleased that we have been able to gather such an accomplished group of people with deep immunology and drug-development experience. I am confident that their collective insight will sharpen our strategy and accelerate advancement of our pipeline." Scientific Advisory Board Janine Schuurman, PhD, is a molecular immunologist who has contributed to six FDA- and EMA-approved therapeutic antibodies, including four therapeutics from Genmab's DuoBody bispecific antibody platform. She spent 22 years at Genmab, most recently as Senior Vice President, Head of Antibody Research and Technology, propelling the discovery and development of investigational therapies to treat cancer and other diseases. Besides serving as an independent biotech consultant providing expert advice to a number of life sciences companies, Janine also serves as board member and President of The Antibody Society. Gavin Thurston, PhD, is a highly experienced R&D executive and scientific leader with over 20 years of experience in oncology research. He previously served as Senior Vice President of Oncology Research at Regeneron, where he played a pivotal role in the successful clinical development of LIBTAYO® and the ongoing late-stage clinical testing of seven other antibodies and bispecific antibodies. Following his time at Regeneron, Dr Thurston has been involved in a number of consultancy projects with antibody therapeutic companies. Paul Parren, PhD, is a molecular immunologist who has contributed to nine FDA- and EMA-approved therapeutic antibodies, including four therapeutics from Genmab's DuoBody bispecific antibody platform. He has spent over 25 years translating antibody knowledge into innovative therapies including 15 years at Genmab, where he headed preclinical R&D. More recently he was head of R&D at LAVA Therapeutics NV, which obtained a NASDAQ listing during his five-year tenure. He currently serves as Professor of Molecular Immunology at Leiden University Medical Centre in The Netherlands, is chairman of the board of The Antibody Society, provides expert advice and is a co-founder and CSO of Gyes BV and its two spin-out companies. Susan Kalled, PhD, is an immunologist with over 25 years of experience spanning early discovery research, clinical drug development and strategic partnerships in the areas of autoimmunity & inflammation, rare diseases and immuno-oncology. Previously she was CSO at Dianthus Therapeutics and Compass Therapeutics. As Vice President of Biology at Q32 Bio, Kalled established the founding research team and played a key role in shaping the company's complement and immunology-focused pipeline. She has also held a number of leadership positions at Biogen and Shire, driving scientific strategy. She currently serves as a scientific strategist and advisor to both early start-ups and established companies. Esper Boel, PhD, is a molecular biologist with 40 years of experience in international biopharmaceutical R&D. He spent 34 years at Novo Nordisk, most recently as Corporate Vice President and Head of Biotechnology. During this time, he was responsible for building and heading a 240+ employee international protein-biotechnology organisation and he established the first international biopharmaceutical R&D centre in Beijing, China. Following his time at Novo Nordisk, he has served as a member of executive teams, on boards and as a senior advisor for a number of high-profile immunology-based companies. Commit Biologics is advancing development of its BiCE™ technology to redefine the treatment of autoimmune disease and cancer. This novel platform is designed to potently activate the complement system to induce highly selective killing of cells implicated in autoimmune disease or tumour cells. BiCE™ uses single domain antibodies that bind to the complement protein C1q, consequently directing the complement system in a highly targeted way against cells of interest. The complement system is part of the body's immune system that has previously been largely untapped therapeutically. The activation of the classical complement pathway, which has a role in health for pathogen defence, begins with the engagement of C1q to antibodies that coat the cell surface, thus initiating multiple effector functions that lead to cell killing. About Commit BiologicsCommit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in autoimmune diseases and cancer. Spun out of Aarhus University, and building on more than three decades of research, Commit's Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumour-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body's natural immune system that leverages both the direct cytolytic activity of complement along with its ability to recruit and activate both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Novo Holdings, Bioqube Ventures and Korys. About the complement systemThe complement system is part of the body's immune system that has previously been largely untapped therapeutically. The activation of the classical complement pathway, which has a role in health for pathogen defence, begins with the engagement of C1q to antibodies that coat the cell surface and ends with the activation of a cytolytic complement complex directly leading to cell lysis. However, current monoclonal antibodies developed for therapeutic purposes have structural restraints that hinder effective engagement to C1q, thus limiting complement mediated cytotoxicity and other complement mediated effector functions. This, plus the presence of natural cell bound complement inhibitors that are often upregulated in disease settings, and low target densities, make conventional therapeutic antibodies poor complement activators. Commit's BiCE™ technology was developed to overcome these barriers, to harness the power of the complement system and direct it towards tumour and immune cells for therapeutic applications. Unleashing this power in a highly targeted way with Commit's technology potentially allows for a broad therapeutic index and the development of highly effective treatments. View original content: SOURCE Commit Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Health
- Yahoo
Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board
LOS ANGELES, May 21, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation ('Trethera'), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the appointment of Benjamin Greenberg, MD, MHS, to its Scientific Advisory Board. Dr. Greenberg will assist in evaluating the clinical development of Trethera's lead asset, TRE-515, in demyelinating autoimmune diseases. A demyelinating disease is any condition that causes damage to the protective covering (myelin sheath) that surrounds nerve fibers. When the myelin sheath is damaged, nerve impulses slow or even stop, causing neurological problems. Dr. Greenberg is an internationally recognized neurologist specializing in rare autoimmune disorders of the central nervous system. He currently serves as Vice Chair of Clinical and Translational Research and Professor of Neurology and Pediatrics at UT Southwestern Medical Center. Dr. Greenberg completed his medical degree at Baylor College of Medicine, followed by an internal medicine internship at Rush–St. Luke's Presbyterian Hospital and a neurology residency at Johns Hopkins Hospital, where he later served as co-director of the Transverse Myelitis Center. Since joining UT Southwestern in 2009, he has founded multiple pioneering programs, including the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program. 'It's fantastic to have Dr. Greenberg join our team,' said Immunology Advisory Board Chairman Dr. Peter M. Clark of UCLA. 'With his addition, we now have an exceptional and purpose-driven team at Trethera with the world's foremost experts from Harvard, Stanford, and UT Southwestern to provide scientific answers as well as enroll patients in our forthcoming neuroimmunology Phase 1 clinical trials to transform patient care.' 'I'm honored to have Dr. Greenberg join the Scientific Advisory Board and support the advancement of TRE-515 as a potential treatment for patients with rare demyelinating diseases,' said Dr. Ken Schultz, Chairman and CEO of Trethera. 'Safe and effective treatments for these neurologic conditions represent a significant unmet need, particularly in pediatric populations, where existing therapies often carry substantial side effects and deliver inconsistent results.' Dr. Greenberg's research and clinical expertise focus on demyelinating and inflammatory disorders such as acute disseminated encephalomyelitis (ADEM), optic neuritis, neuromyelitis optica spectrum disorder (NMOSD), and transverse myelitis. As the principal investigator of major national collaborative studies, he has contributed extensively to the discovery of novel biomarkers and the development of biorepository protocols that support precision diagnostics and treatment strategies. Dr. Greenberg's appointment to the Scientific Advisory Board further strengthens Trethera's commitment to advancing innovative therapies for autoimmune neurologic diseases. Trethera's clinical stage and first-in-class drug, TRE-515, holds FDA Orphan Drug status for both optic neuritis and ADEM. FDA Orphan Drug designation confers substantial advantages, including a faster path to market approval, FDA assistance in designing clinical trials, exemption from the $4M drug approval application fee, and eligibility for seven years of marketing exclusivity. Should the FDA approve TRE-515 for commercial use in ADEM, Trethera would be eligible for a pediatric priority review voucher. TRE-515 is currently being evaluated in a Phase 1 dose escalation solid tumors clinical trial. ADEM is an autoimmune disease, affecting 15,000 patients a year in the United States, with most cases occurring in six to eight year-old children. ADEM can present with fever and difficulty walking that progresses to loss of consciousness, coma, and even death. Optic neuritis typically occurs in adult patients, manifesting with rapid vision loss in one or both eyes, with up to one in four patients never fully recovering their eyesight. Over 100,000 cases of optic neuritis occur annually in the US and have a close association with multiple sclerosis (MS). Figure 1: Representative stained sections of the optic nerve from mice experiencing optic neuritis. Arrows point to regions of leukocyte infiltration. Sources: Cleveland Clinic 2021; Bennett 2019; Yang 2017; Wilhelm 2015 About Trethera Trethera is a clinical stage, privately held, biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera's innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally administered capsule twice designated by the FDA as an Orphan Drug. TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth, and certain autoimmune diseases might also respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination to precisely target a metabolic vulnerability of cancer or autoimmune diseases that will transform outcomes for patients. For more information, please visit us at or e-mail Investor Relations at ir@ You can also follow Trethera on Facebook and LinkedIn. Note on Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are 'forward-looking statements,' which may often, but not always, be identified by the use of such words as "may," "might," "will," "will likely result," "would," "should," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "continue," "target" or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera's control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. A photo accompanying this announcement is available at in to access your portfolio
Business Wire
14-05-2025
- Health
- Business Wire
Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain
PHILADELPHIA--(BUSINESS WIRE)-- Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, 'AAVs engineered for robust brain transduction drive therapeutically relevant expression of secreted recombinant protein in NHPs and a mouse model of lysosomal storage disease.' "This breakthrough in AAV capsid engineering represents a critical advancement in the field of gene therapy," said Dr. Beverly Davidson, Chair of the Scientific Advisory Board of Latus Bio and corresponding author of the study. The study, led by Latus founder Beverly Davidson, PhD details the development of a novel adeno-associated virus (AAV) capsid variant - AAV-Ep+ - that demonstrates unprecedented potency in transducing cells that line the ventricles, known as ependymal cells, and cerebral neurons in mice and in non-human primates (NHPs). This advancement is potentially a significant leap forward for therapeutic gene delivery, wherein the study authors demonstrate that cells transduced with AAV-Ep+ can effectively serve as protein production depots, secreting large amounts of soluble proteins into the cerebral spinal fluid (CSF) for uptake throughout the central nervous system (CNS). This potency and distribution profile could potentially result in one-time delivery of gene therapies that encode protein treatments for lysosomal storage disorders (LSDs) as well as for other neurodevelopmental and neurodegenerative diseases that result in long term benefits for patients. The AAV-Ep+ capsid variant was identified through a massively parallelled and unbiased screen of a large-diversity AAV variant library administered to NHPs. The nominated capsid, which was isolated from tens of millions of potential candidates, displays: Remarkable tropism for cells that line the ventricular system of the brain and spinal cord of adult NHPs and mice. It also efficiently transduces neurons in cortical regions of the brain that are implicated in many diseases. Robust transduction of induced pluripotent stem cell (iPSC)-derived human neurons and mice when compared to naturally occurring AAV serotypes. This cross-species activity highlights the potential for AAV-Ep+ to deliver sustained and therapeutic expression of encoded proteins in human brain cells that could result in prolonged therapeutic benefit for patients. Low dose administration of AAV-Ep+ constructs designed to express human tripeptidyl peptidase (hTPP1) to mice deficient in TPP1 (a model of human CLN2 disease - a type of LSD) as well as to NHPs result in CSF and parenchymal tissue levels that exceeded those obtained with natural serotype capsids, reaching levels that are potentially multi-fold above therapeutic values required for CLN2 patients. "This breakthrough in AAV capsid engineering represents a critical advancement in the field of gene therapy," said Dr. Beverly Davidson, Chair of the Scientific Advisory Board of Latus Bio and corresponding author of the study. "AAV-Ep+ offers a highly efficient, low-dose solution for brain-wide protein delivery, opening new possibilities for treating neurodevelopmental diseases like CLN2 disease and beyond." The study showcases Latus' unique capsid discovery platform and ability to identify AAV capsid variants that are optimized for delivery to specific tissues and cell types, seeking to address translational shortcomings to prospectively enable better gene therapies. Latus continues to advance its pipeline of novel AAV capsid variants that target disease-relevant cell types in other regions of the central nervous system (e.g., cortex, cerebellum, spinal cord) as well as in peripheral tissues (e.g., ear, eye, heart, kidney and muscle). The Company is developing cutting-edge gene therapies that aim to transform the treatment landscape of genetically defined diseases, including many with high unmet medical needs. About Latus Bio (Latus) Latus is a biotechnology company dedicated to addressing devastating CNS and peripheral diseases via gene therapy. The Company is advancing an innovative therapeutics pipeline based on novel AAV capsid variants with potency and specificity. Latus is powered by a diverse team of visionary scientists, experienced clinicians, and leading industry executives. The Company has offices in Philadelphia, PA and in the Seaport in Boston, MA. For more information, visit and follow on LinkedIn.
Globe and Mail
13-05-2025
- Business
- Globe and Mail
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the 'Company' or 'Nexalin') the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, each of whom brings specialized expertise that aligns with Nexalin's Alzheimer's-focused initiatives. The restructured SAB will play a pivotal role in guiding the Company's scientific direction, clinical strategy, and biomarker-driven trial design for neurodegenerative and neuropsychiatric disorders. 'This enhanced advisory board reflects our sharpened focus on Alzheimer's disease, and the high-caliber expertise of Drs. Huang, Owens, and Scheer aligns with our expanding research agenda,' said Mark White, CEO of Nexalin Technology. 'Their combined contributions will be invaluable as we advance Nexalin's technology through clinical trials designed to address one of the greatest public health challenges of our time.' Nexalin's Gen-2 SYNC and Gen-3 Halo™ headset delivers DIFS™, a proprietary waveform capable of penetrating deep brain structures implicated in cognitive decline and mental illness. Recent published articles and encouraging preclinical and early-stage human data suggest that DIFS™ may promote neuroplasticity and functional recovery in regions associated with memory and executive function. These findings have prompted the Company to intensify its focus on Alzheimer's disease, with the SAB's restructuring aimed at providing the scientific and clinical oversight required for this complex area of medicine. Scientific Advisory Board Members Dr. Mingxiong Huang is a globally recognized expert in magnetoencephalography (MEG) and neuroimaging, with over 25 years of experience developing and applying advanced imaging techniques to neurological and psychiatric disorders. He is Professor of Radiology at the University of California, San Diego (UCSD), Adjunct Professor in the Department of Electrical and Computer Engineering, Co-Director of the UCSD MEG Center, and a career research health scientist at the VA San Diego Healthcare System. Dr. Huang earned his Ph.D. in biomedical physics from Northeastern University and completed postdoctoral training in MEG at Los Alamos National Laboratory. He previously held faculty positions at the University of New Mexico before joining UCSD. His work has been instrumental in advancing MEG source imaging, integrating MEG with structural and functional modalities such as diffusion tensor imaging, and applying these methods to conditions including TBI, PTSD, stroke, epilepsy, and schizophrenia. He has authored over 90 peer-reviewed publications and received the Distinguished Investigator Award from the Academy of Radiology Research. Dr. Huang's deep expertise in brain imaging biomarkers directly supports Nexalin's mission to develop data-driven, non-invasive therapies for Alzheimer's and other neurodegenerative disorders. Dr. Abe Scheer served on the Company's prior SAB and brings more than four decades of experience in adult and pediatric neurology, psychiatry, brain injury medicine, and electrophysiology. Board certified by the American Board of Psychiatry and Neurology in both adult and pediatric neurology, as well as in brain injury medicine, Dr. Scheer has trained and held faculty positions at premier institutions including Columbia University, Cornell Medical College, Georgetown University, and the University of Pittsburgh. Dr. Scheer held the position of Director of Neurology and Stroke Services at Beebe Healthcare in Delaware for over 10 years. He is currently a neurohospitalist and neurointensivist at Bay Health in Delaware and maintains an attending role at MeadowWood Hospital in Delaware. Dr. Scheer has lectured extensively across the U.S. on neuromodulation therapies and was instrumental in launching the first vagal nerve stimulation and baclofen pump clinics in Lincoln, Nebraska. He has served in advisory capacities for leading device developers including Medtronic, Cyberonics, and Milestone Scientific. A passionate educator, he continues to teach medical students and residents while contributing to clinical advancements in both neurology and psychiatry. His expertise will play a critical role in supporting Nexalin's efforts to deliver innovative, non-pharmacological solutions for Alzheimer's and related disorders. Dr. David Owens serves as the Company's Chief Medical Officer and is a board-certified neuroradiologist and interventional neuroimaging specialist with more than 25 years of experience in brain and spine imaging. A graduate of Furman University and the Medical University of South Carolina, Dr. Owens completed residency and fellowship training at Emory University Hospital, where he specialized in interventional therapies for brain disorders before entering private practice. His expertise includes traumatic brain injury, neurocognitive disorders, and sports-related brain trauma. Dr. Owens is a nationally recognized leader in advanced imaging techniques such as diffusion tensor imaging (DTI) and functional MRI. Over the past decade, he has also conducted and contributed to clinical research on transcranial stimulation therapies for conditions including anxiety, insomnia, clinical depression, and chronic pain—particularly in the context of reducing opioid dependency. Today, he operates a national teleradiology consultation practice focused on outpatient neuroimaging and continues to serve as a strategic clinical advisor in emerging neuromodulation technologies. 'This is a critical moment for innovation in Alzheimer's treatment,' said Dr. Scheer. 'Nexalin's technology represents a novel approach to brain modulation that could complement or even exceed the efficacy of traditional pharmacological therapies, particularly in the early stages of disease.' The Company plans to initiate new Alzheimer's-focused clinical studies in the third quarter of 2025, incorporating cognitive testing, imaging biomarkers, and MEG-guided metrics to assess treatment efficacy and neural activation. The SAB will be instrumental in optimizing trial designs and ensuring adherence to regulatory standards and scientific rigor. 'I am excited to work alongside Nexalin's leadership and fellow SAB members to help guide the next generation of non-invasive neuromodulation therapies,' added Dr. Huang. 'The intersection of neuroimaging, brain stimulation, and clinical science holds enormous potential for treating neurodegenerative disease.' This SAB reconstitution underscores Nexalin's continued evolution as a science-driven company committed to transforming mental health and neurodegenerative disease care through advanced bioelectronic medicine. About Nexalin Technology, Inc. Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15-milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: Forward-looking statements This press release contains statements that constitute 'forward-looking statements,' These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management 'believes', 'expects', 'anticipates', 'plans', 'intends' and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
